- Trial phase
- Phase 3
- Time to market
- If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
- Why 7/10
- The next hard catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (imminent as of November 13, 2026). This feedback will determine whether the RECOVER-2 Phase 3 trial can proceed with the new formulation and what additional steps are needed before an NDA submission. The stock trades at $0.34 on OTCQB with a ~$10M market cap, and this binary regulatory event is the single most important near-term driver.
The immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.
Price Chart
Executive Summary
Brilaroxazine (RP5063) is Reviva Pharmaceuticals' lead drug candidate, a novel serotonin-dopamine stabilizer in development for schizophrenia and other indications. The Phase 3 RECOVER trial met its primary endpoint in 2023, but the FDA required a second Phase 3 trial (RECOVER-2) before an NDA can be submitted, causing the stock to crash 50% in December 2025. As of November 2026, the company is awaiting FDA feedback on a new formulation of brilaroxazine for use in RECOVER-2, expected in Q4 2026. The stock trades at $0.34 on OTCQB (delisted from Nasdaq in May 2026) with $17.5M in cash, and patient enrollment in RECOVER-2 is contingent on additional financing. Brilaroxazine also received FDA Orphan Drug Designation for pulmonary arterial hypertension (PAH) in April 2026.
How It Works
Brilaroxazine is a novel serotonin-dopamine stabilizer. It works by binding to and modulating several serotonin and dopamine receptors in the brain that are believed to play key roles in schizophrenia and its symptoms. Unlike many older antipsychotics that mainly block dopamine, brilaroxazine aims to balance both serotonin and dopamine signaling, which may help treat a wider range of symptoms (including negative symptoms like social withdrawal) with fewer side effects.
Trial Status
The pivotal Phase 3 RECOVER double-blind trial met its primary endpoint in October 2023. A one-year open-label extension (OLE) study completed with 446 participants, showing sustained efficacy and safety. The FDA recommended a second Phase 3 trial (RECOVER-2) in December 2025. As of Q3 2026, the company is awaiting FDA feedback on a new formulation before initiating RECOVER-2, with a bioequivalence study expected in Q1 2027 and patient enrollment in 1H 2027, subject to additional financing.
The Two-Sided Case
Upcoming Catalysts
- FDA feedback on new brilaroxazine formulation for RECOVER-2 trial and NDA submission (expected Q4 2026, imminent)
- Bioequivalence study for new formulation (expected Q1 2027)
- RECOVER-2 Phase 3 patient enrollment (expected 1H 2027, subject to financing)
- Potential Nasdaq relisting application (expected 1H 2027)
- Composition of matter patent application priority examination outcome (Track 1)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Reviva Pharmaceuticals PRESS-RELEASE RVPH ·Originating report